Breaking News Instant updates and real-time market news.

GILD

Gilead

$63.85 /

+0.55 (+0.87%)

, GLPG

Galapagos

$146.51 /

+5.54 (+3.93%)

09:20
10/12/20
10/12
09:20
10/12/20
09:20

Gilead, Galapagos presents data from Phase 2b/3 trial of filgotinib

Gilead Sciences (GILD) and Galapagos (GLPG) presented late-breaking data demonstrating sustained efficacy and safety with filgotinib, an investigational, oral, once-daily, JAK1 preferential inhibitor, for the treatment of moderately to severely active ulcerative colitis. The data from the randomized, double-blind, placebo-controlled, Phase 2b/3 SELECTION trial showed that a significantly higher proportion of patients treated with filgotinib 200 mg, versus placebo, achieved clinical remission at Week 10 and maintained remission through Week 58. In addition, significantly more patients achieved six-month corticosteroid-free remission. The full results were presented today at the 2020 United European Gastroenterology Week Virtual Meeting. UC is a longer-term condition characterized by inflammation of the mucosal lining of the colon and rectum. An increasingly prevalent disease, UC has a significant impact on the quality of life of more than 2 million people around the world. Despite current treatments, many patients experience fecal urgency, incontinence, recurring bloody diarrhea, and the need to empty their bowels frequently, often accompanied by abdominal pain, poor sleep and fatigue. The SELECTION study included biologic-naive patients, for whom prior conventional therapy had failed, as well as biologic-experienced patients, a high proportion of whom had been non-responders to at least two different lines of prior biologics. In total, 43 percent of patients in the biologic-experienced cohort had failed treatment with both a TNF inhibitor and vedolizumab. The study allowed the enrollment of patients who were taking steroids, and/or immunomodulators, including methotrexate, mercaptopurine or azathioprine, as they would in real-world clinical practice. Overall, 1,348 biologic-naive or biologic-experienced adult patients with moderately to severely active UC were randomized and treated in the SELECTION study. Among biologic-naive patients treated with filgotinib 200 mg, a significantly higher proportion of patients achieved clinical remission at Week 10 compared with placebo. Additionally, a significantly higher proportion of biologic-naive patients treated with filgotinib 200 mg versus placebo achieved Mayo Clinic Score remission, endoscopic remission and histologic remission. A significantly higher proportion of biologic-experienced patients treated with filgotinib 200mg achieved clinical remission at Week 10 compared with placebo. Patients treated with filgotinib who achieved clinical response or remission at Week 10 were re-randomized to their induction dose of filgotinib or placebo in a 2:1 ratio and treated through Week 58. At Week 58, 37.2 percent of patients receiving filgotinib 200 mg achieved clinical remission, compared with 11.2 percent of patients treated with placebo. A significantly higher proportion of those treated with filgotinib 200 mg versus placebo achieved sustained clinical remission, MCS remission, endoscopic remission and histologic remission. Additionally, a significantly higher proportion of patients treated with filgotinib 200 mg achieved six-month corticosteroid-free clinical remission at Week 58 compared with placebo. Overall, the incidence of adverse events, serious AEs and discontinuations due to AEs were similar in the filgotinib and placebo groups in both the induction and maintenance periods of the study. Serious infections, herpes zoster, venous thrombosis, pulmonary embolism and gastrointestinal perforation were infrequent and comparable across treatment groups. The most common adverse events of interest in the induction trials were serious infections, herpes zoster, opportunistic infections and pulmonary embolism. In the maintenance trial, the most common adverse events of interest were serious infections, herpes zoster and venous thrombosis. Two deaths were observed in the filgotinib 200 mg treatment group in the maintenance trial; both adverse events leading to deaths were considered by the study investigators to be unrelated to study drug.

GILD

Gilead

$63.85 /

+0.55 (+0.87%)

GLPG

Galapagos

$146.51 /

+5.54 (+3.93%)

  • 06

    Nov

GILD Gilead
$63.85 /

+0.55 (+0.87%)

09/30/20 Jefferies
Regeneron antibody cocktail results positive for vaccines, says Jefferies
09/24/20 H.C. Wainwright
Durect study designed to support full approval, says H.C. Wainwright
09/20/20 Citi
Immunomedics presents at ESMO, readouts exceeded expectations, says Citi
09/18/20 RBC Capital
Gilead price target raised to $86 from $82 at RBC Capital
GLPG Galapagos
$146.51 /

+5.54 (+3.93%)

10/08/20 UBS
Galapagos price target raised to EUR 135 from EUR 130 at UBS
09/24/20 JPMorgan
Galapagos price target lowered to EUR 130 from EUR 185 at JPMorgan
08/25/20
Fly Intel: Top five analyst downgrades
08/25/20 Jefferies
Galapagos downgraded to Hold from Buy at Jefferies

TODAY'S FREE FLY STORIES

Conference/Events
Clene participates in a conference call with Benchmark » 13:52
03/03/21
03/03
13:52
03/03/21
13:52
CLNN

Clene

$13.80 /

-0.2 (-1.43%)

Healthcare Analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CLNN Clene
$13.80 /

-0.2 (-1.43%)

CLNN Clene
$13.80 /

-0.2 (-1.43%)

03/02/21 Benchmark
Clene initiated with a Buy at Benchmark
02/03/21 Roth Capital
Clene initiated with a Buy at Roth Capital
Hot Stocks
Elanco off lows, turns positive after WSJ report of Starboard board nominations » 13:47
03/03/21
03/03
13:47
03/03/21
13:47
ELAN

Elanco

$30.96 /

-1.445 (-4.46%)

Shares of Elanco have…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ELAN Elanco
$30.96 /

-1.445 (-4.46%)

ELAN Elanco
$30.96 /

-1.445 (-4.46%)

02/26/21 Barclays
Judge allows challenge to Elanco's Experior, says Barclays
02/26/21
Fly Intel: Top five analyst upgrades
02/26/21 Credit Suisse
Elanco upgraded to Outperform from Neutral at Credit Suisse
12/18/20 Alliance Global Partners
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners
ELAN Elanco
$30.96 /

-1.445 (-4.46%)

  • 01
    Dec
ELAN Elanco
$30.96 /

-1.445 (-4.46%)

ELAN Elanco
$30.96 /

-1.445 (-4.46%)

ELAN Elanco
$30.96 /

-1.445 (-4.46%)

Options
AIG call volume above normal and directionally bullish » 13:45
03/03/21
03/03
13:45
03/03/21
13:45
AIG

AIG

$47.49 /

+1.52 (+3.31%)

Bullish option flow…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
AIG AIG
$47.49 /

+1.52 (+3.31%)

AIG AIG
$47.49 /

+1.52 (+3.31%)

03/01/21 Credit Suisse
AIG price target raised to $42 from $35 at Credit Suisse
02/26/21 Atlantic Equities
AIG upgraded to Overweight from Neutral at Atlantic Equities
02/19/21 Deutsche Bank
AIG price target raised to $44 from $38 at Deutsche Bank
02/18/21 RBC Capital
AIG price target raised to $49 from $39 at RBC Capital
AIG AIG
$47.49 /

+1.52 (+3.31%)

AIG AIG
$47.49 /

+1.52 (+3.31%)

AIG AIG
$47.49 /

+1.52 (+3.31%)

AIG AIG
$47.49 /

+1.52 (+3.31%)

General news
February Beige Book to be released at 14:00  13:45
03/03/21
03/03
13:45
03/03/21
13:45
 
Periodicals
Activist Starboard takes stake in Elanco, makes board nominations, WSJ says  13:44
03/03/21
03/03
13:44
03/03/21
13:44
ELAN

Elanco

$31.10 /

-1.305 (-4.03%)

 
ShowHide Related Items >><<
ELAN Elanco
$31.10 /

-1.305 (-4.03%)

ELAN Elanco
$31.10 /

-1.305 (-4.03%)

02/26/21 Barclays
Judge allows challenge to Elanco's Experior, says Barclays
02/26/21
Fly Intel: Top five analyst upgrades
02/26/21 Credit Suisse
Elanco upgraded to Outperform from Neutral at Credit Suisse
12/18/20 Alliance Global Partners
Kindred Biosciences price target lowered to $9.25 from $10.25 at Alliance Global Partners
ELAN Elanco
$31.10 /

-1.305 (-4.03%)

  • 01
    Dec
ELAN Elanco
$31.10 /

-1.305 (-4.03%)

ELAN Elanco
$31.10 /

-1.305 (-4.03%)

ELAN Elanco
$31.10 /

-1.305 (-4.03%)

Recommendations
ICF International price target raised to $96 from $88 at Barrington » 13:40
03/03/21
03/03
13:40
03/03/21
13:40
ICFI

ICF International

$88.13 /

+1.32 (+1.52%)

Barrington analyst Kevin…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ICFI ICF International
$88.13 /

+1.32 (+1.52%)

ICFI ICF International
$88.13 /

+1.32 (+1.52%)

02/26/21 Canaccord
ICF International price target raised to $100 from $80 at Canaccord
01/15/21 Truist
ICF International price target raised to $102 from $95 at Truist
01/06/21 Barrington
Imax and Sirius XM among Barrington's best ideas for 2021
07/01/20 Berenberg
ICF International upgraded to Buy from Hold at Berenberg
ICFI ICF International
$88.13 /

+1.32 (+1.52%)

Conference/Events
Acco Brands management to meet virtually with Barrington » 13:39
03/03/21
03/03
13:39
03/03/21
13:39
ACCO

Acco Brands

$8.54 /

+0.26 (+3.14%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
ACCO Acco Brands
$8.54 /

+0.26 (+3.14%)

ACCO Acco Brands
$8.54 /

+0.26 (+3.14%)

11/16/20 Barrington
Acco Brands price target raised to $12 from $9 at Barrington
11/12/20
Fly Intel: Top five analyst upgrades
11/12/20 KeyBanc
Acco Brands upgraded to Overweight from Sector Weight at KeyBanc
05/08/20 Barrington
Acco Brands price target lowered to $9 from $13 at Barrington
ACCO Acco Brands
$8.54 /

+0.26 (+3.14%)

ACCO Acco Brands
$8.54 /

+0.26 (+3.14%)

Conference/Events
ICF International management to meet virtually with Barrington » 13:38
03/03/21
03/03
13:38
03/03/21
13:38
ICFI

ICF International

$88.13 /

+1.32 (+1.52%)

Virtual Meeting to be…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ICFI ICF International
$88.13 /

+1.32 (+1.52%)

ICFI ICF International
$88.13 /

+1.32 (+1.52%)

02/26/21 Canaccord
ICF International price target raised to $100 from $80 at Canaccord
01/15/21 Truist
ICF International price target raised to $102 from $95 at Truist
01/06/21 Barrington
Imax and Sirius XM among Barrington's best ideas for 2021
07/01/20 Berenberg
ICF International upgraded to Buy from Hold at Berenberg
ICFI ICF International
$88.13 /

+1.32 (+1.52%)

Hot Stocks
Facebook resuming political, electoral, social issue ads tomorrow » 13:37
03/03/21
03/03
13:37
03/03/21
13:37
FB

Facebook

$257.76 /

-1.05 (-0.41%)

Facebook said on its…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
FB Facebook
$257.76 /

-1.05 (-0.41%)

FB Facebook
$257.76 /

-1.05 (-0.41%)

02/26/21 Jefferies
Twitter price target raised to $79 from $64 at Jefferies
02/16/21 Loop Capital
Facebook price target raised to $370 from $330 at Loop Capital
02/10/21 Tigress Financial
Facebook has 'significant upside' at current levels, says Tigress
02/01/21 Truist
Alphabet price target raised to $2,100 from $2,000 at Truist
FB Facebook
$257.76 /

-1.05 (-0.41%)

FB Facebook
$257.76 /

-1.05 (-0.41%)

FB Facebook
$257.76 /

-1.05 (-0.41%)

FB Facebook
$257.76 /

-1.05 (-0.41%)

Recommendations
Valeo price target lowered to EUR 35 from EUR 38 at JPMorgan » 13:37
03/03/21
03/03
13:37
03/03/21
13:37
VLEEY

Valeo

$0.00 /

+ (+0.00%)

JPMorgan analyst Jose…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
VLEEY Valeo
$0.00 /

+ (+0.00%)

12:54 Today UBS
Valeo price target raised to EUR 40 from EUR 31 at UBS
02/26/21 RBC Capital
Valeo price target raised to EUR 27 from EUR 26 at RBC Capital
02/25/21 Citi
Valeo downgraded to Sell from Neutral at Citi
02/22/21 Berenberg
Valeo price target raised to EUR 39 from EUR 37 at Berenberg
Recommendations
Swiss Life price target raised to CHF 460 from CHF 440 at JPMorgan » 13:36
03/03/21
03/03
13:36
03/03/21
13:36
SZLMY

Swiss Life

$0.00 /

+ (+0.00%)

JPMorgan analyst Ashik…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SZLMY Swiss Life
$0.00 /

+ (+0.00%)

13:10 Today Credit Suisse
Swiss Life price target raised to CHF 455 from CHF 365 at Credit Suisse
01/21/21 JPMorgan
Swiss Life price target raised to CHF 440 from CHF 350 at JPMorgan
01/08/21 Berenberg
Swiss Life price target raised to CHF 501.80 from CHF 450.50 at Berenberg
01/06/21 Citi
Swiss Life initiated with a Buy at Citi
Recommendations
Royal Dutch Shell price target raised to 2,000 GBp from 1,700 GBp at JPMorgan » 13:36
03/03/21
03/03
13:36
03/03/21
13:36
RDS.B

Royal Dutch Shell

$40.49 /

+1.175 (+2.99%)

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
RDS.B Royal Dutch Shell
$40.49 /

+1.175 (+2.99%)

RDS.B Royal Dutch Shell
$40.49 /

+1.175 (+2.99%)

02/12/21 Scotiabank
Royal Dutch Shell upgraded to Sector Perform from Underperform at Scotiabank
01/27/21 JPMorgan
Royal Dutch Shell price target lowered to 1,700 GBp from 1,800 GBp at JPMorgan
01/15/21 JPMorgan
Royal Dutch Shell price target raised to 1,800 GBp from 1,700 GBp at JPMorgan
12/23/20 MKM Partners
Royal Dutch Shell initiated with a Buy at MKM Partners
RDS.B Royal Dutch Shell
$40.49 /

+1.175 (+2.99%)

RDS.B Royal Dutch Shell
$40.49 /

+1.175 (+2.99%)

RDS.B Royal Dutch Shell
$40.49 /

+1.175 (+2.99%)

Recommendations
Royal Dutch Shell price target raised to 2,000 GBp from 1,700 GBp at JPMorgan » 13:36
03/03/21
03/03
13:36
03/03/21
13:36
RDS.A

Royal Dutch Shell

$42.66 /

+1.1 (+2.65%)

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
RDS.A Royal Dutch Shell
$42.66 /

+1.1 (+2.65%)

RDS.A Royal Dutch Shell
$42.66 /

+1.1 (+2.65%)

02/12/21 Scotiabank
Royal Dutch Shell upgraded to Sector Perform from Underperform at Scotiabank
02/08/21 Cowen
Royal Dutch Shell price target lowered to $45 from $50 at Cowen
01/27/21 JPMorgan
Royal Dutch Shell price target lowered to 1,700 GBp from 1,800 GBp at JPMorgan
01/21/21 Jefferies
Royal Dutch Shell initiated with a Buy at Jefferies
RDS.A Royal Dutch Shell
$42.66 /

+1.1 (+2.65%)

RDS.A Royal Dutch Shell
$42.66 /

+1.1 (+2.65%)

RDS.A Royal Dutch Shell
$42.66 /

+1.1 (+2.65%)

Recommendations
Repsol price target raised to EUR 12 from EUR 8.50 at JPMorgan » 13:35
03/03/21
03/03
13:35
03/03/21
13:35
REPYY

Repsol

$0.00 /

+ (+0.00%)

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
REPYY Repsol
$0.00 /

+ (+0.00%)

02/22/21 Berenberg
Repsol price target raised to EUR 9.70 from EUR 9 at Berenberg
02/19/21 Credit Suisse
Repsol price target raised to EUR 10.80 from EUR 10.30 at Credit Suisse
02/19/21 Barclays
Repsol price target raised to EUR 10 from EUR 9 at Barclays
02/19/21 Morgan Stanley
Repsol upgraded to Equal Weight from Underweight at Morgan Stanley
Recommendations
OMV AG price target raised to EUR 50 from EUR 44 at JPMorgan » 13:35
03/03/21
03/03
13:35
03/03/21
13:35
OMVKY

OMV AG

$0.00 /

+ (+0.00%)

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
OMVKY OMV AG
$0.00 /

+ (+0.00%)

OMVKY OMV AG
$0.00 /

+ (+0.00%)

02/16/21 UBS
OMV AG upgraded to Buy from Neutral at UBS
02/05/21 Barclays
OMV AG price target raised to EUR 40 from EUR 35 at Barclays
02/05/21 Credit Suisse
OMV AG price target lowered to EUR 45 from EUR 47.50 at Credit Suisse
01/21/21 Jefferies
OMV AG initiated with a Buy at Jefferies
Recommendations
Man Group price target raised to 180 GBp from 170 GBp at JPMorgan » 13:34
03/03/21
03/03
13:34
03/03/21
13:34
MNGPF

Man Group

$0.00 /

+ (+0.00%)

JPMorgan analyst Gurjit…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
MNGPF Man Group
$0.00 /

+ (+0.00%)

13:09 Today Credit Suisse
Man Group price target raised to 175 GBp from 160 GBp at Credit Suisse
02/22/21 Barclays
Man Group price target raised to 160 GBp from 145 GBp at Barclays
02/01/21 Berenberg
Man Group price target raised to 163 GBp from 138 GBp at Berenberg
12/17/20 Credit Suisse
Man Group upgraded to Outperform from Neutral at Credit Suisse
Recommendations
Vir Biotechnology price target lowered to $59 from $61 at Goldman Sachs » 13:34
03/03/21
03/03
13:34
03/03/21
13:34
VIR

Vir Biotechnology

/

+

Goldman Sachs analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
VIR Vir Biotechnology
/

+

VIR Vir Biotechnology
/

+

11:37 Today H.C. Wainwright
Vir Biotechnology selloff a 'terrific buying opportunity,' says H.C. Wainwright
02/25/21 Barclays
Vir Biotechnology price target raised to $77 from $61 at Barclays
01/27/21 JPMorgan
Vir Biotechnology added to analyst focus list as short idea at JPMorgan
01/27/21 H.C. Wainwright
Vir collaboration gives H.C. Wainwright more confidence in COVID-19 program
VIR Vir Biotechnology
/

+

  • 08
    Jul
VIR Vir Biotechnology
/

+

Recommendations
Equinor price target raised to NOK 210 from NOK 190 at JPMorgan » 13:34
03/03/21
03/03
13:34
03/03/21
13:34
EQNR

Equinor

$19.49 /

+0.245 (+1.27%)

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
EQNR Equinor
$19.49 /

+0.245 (+1.27%)

EQNR Equinor
$19.49 /

+0.245 (+1.27%)

02/11/21 RBC Capital
Equinor price target lowered to NOK 210 from NOK 220 at RBC Capital
01/21/21 Jefferies
Equinor initiated with a Buy at Jefferies
01/21/21 Santander
Equinor downgraded to Hold from Buy at Santander
01/15/21 JPMorgan
Equinor price target raised to NOK 190 from NOK 180 at JPMorgan
Recommendations
Eni SpA price target raised to EUR 11 from EUR 9 at JPMorgan » 13:33
03/03/21
03/03
13:33
03/03/21
13:33
E

Eni SpA

$23.49 /

+0.48 (+2.09%)

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
E Eni SpA
$23.49 /

+0.48 (+2.09%)

02/24/21 UBS
Eni SpA price target raised to EUR 11.75 from EUR 11.50 at UBS
02/23/21 Berenberg
Eni SpA price target raised to EUR 10 from EUR 9 at Berenberg
02/23/21 DZ Bank
Eni SpA upgraded to Hold from Sell at DZ Bank
02/22/21 RBC Capital
Eni SpA upgraded to Sector Perform from Underperform at RBC Capital
Recommendations
BP price target raised to 440 GBp from 415 GBp at JPMorgan » 13:33
03/03/21
03/03
13:33
03/03/21
13:33
BP

BP

$25.93 /

+1.17 (+4.73%)

JPMorgan analyst…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
BP BP
$25.93 /

+1.17 (+4.73%)

BP BP
$25.93 /

+1.17 (+4.73%)

02/16/21 Scotiabank
Scotiabank upgrades BP to Outperform amid 'rock bottom sentiment'
02/16/21 Scotiabank
BP upgraded to Outperform from Sector Perform at Scotiabank
02/03/21 RBC Capital
BP price target lowered to 280 GBp from 310 GBp at RBC Capital
02/03/21 Credit Suisse
BP price target lowered to 350 GBp from 380 GBp at Credit Suisse
BP BP
$25.93 /

+1.17 (+4.73%)

BP BP
$25.93 /

+1.17 (+4.73%)

BP BP
$25.93 /

+1.17 (+4.73%)

Recommendations
AIB Group price target raised to EUR 2.10 from EUR 1.90 at JPMorgan » 13:32
03/03/21
03/03
13:32
03/03/21
13:32
AIBRF

AIB Group

$0.00 /

+ (+0.00%)

JPMorgan analyst Raul…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
AIBRF AIB Group
$0.00 /

+ (+0.00%)

01/18/21 Exane BNP Paribas
AIB Group upgraded to Outperform from Neutral at Exane BNP Paribas
01/04/21 Keefe Bruyette
AIB Group downgraded to Market Perform from Outperform at Keefe Bruyette
12/07/20 UBS
AIB Group price target raised to EUR 2.15 from EUR 1.40 at UBS
12/07/20 Barclays
AIB Group downgraded to Equal Weight from Overweight at Barclays
Recommendations
Acerinox price target raised to EUR 12 from EUR 11.40 at JPMorgan » 13:32
03/03/21
03/03
13:32
03/03/21
13:32
ANIOY

Acerinox

$0.00 /

+ (+0.00%)

JPMorgan analyst Luke…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
ANIOY Acerinox
$0.00 /

+ (+0.00%)

03/02/21 Credit Suisse
Acerinox price target raised to EUR 10 from EUR 9.50 at Credit Suisse
03/01/21 Deutsche Bank
Acerinox price target raised to EUR 14 from EUR 13 at Deutsche Bank
02/02/21 Morgan Stanley
Aperam downgraded to Equal Weight from Overweight at Morgan Stanley
02/02/21 Morgan Stanley
Acerinox upgraded to Overweight from Equal Weight at Morgan Stanley
Hot Stocks
General Dynamics raises quarterly dividend 8% to $1.19 per share » 13:31
03/03/21
03/03
13:31
03/03/21
13:31
GD

General Dynamics

$168.67 /

+1 (+0.60%)

The board of General…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
GD General Dynamics
$168.67 /

+1 (+0.60%)

GD General Dynamics
$168.67 /

+1 (+0.60%)

01/29/21 Susquehanna
General Dynamics price target raised to $180 from $162 at Susquehanna
11/03/20 Morgan Stanley
Morgan Stanley sees attractive buying opportunity in Defense stocks
10/29/20 Credit Suisse
General Dynamics price target lowered to $140 from $156 at Credit Suisse
10/02/20
Fly Intel: Top five analyst downgrades
GD General Dynamics
$168.67 /

+1 (+0.60%)

GD General Dynamics
$168.67 /

+1 (+0.60%)

GD General Dynamics
$168.67 /

+1 (+0.60%)

Hot Stocks
North American rail traffic rose 2.2% in week ended February 27, AAR reports » 13:31
03/03/21
03/03
13:31
03/03/21
13:31
CNI

Canadian National

$111.53 /

-0.41 (-0.37%)

, CP

Canadian Pacific

$362.88 /

-4.155 (-1.13%)

, CSX

CSX

$91.87 /

-0.26 (-0.28%)

, KSU

Kansas City Southern

$207.00 /

-3.04 (-1.45%)

, NSC

Norfolk Southern

$256.04 /

-0.51 (-0.20%)

, UNP

Union Pacific

$208.02 /

-1.15 (-0.55%)

, GWR

Genesee & Wyoming

$111.91 /

+ (+0.00%)

The Association of…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return in 9 minutes

Get Free Trial

ShowHide Related Items >><<
CNI Canadian National
$111.53 /

-0.41 (-0.37%)

CP Canadian Pacific
$362.88 /

-4.155 (-1.13%)

CSX CSX
$91.87 /

-0.26 (-0.28%)

KSU Kansas City Southern
$207.00 /

-3.04 (-1.45%)

NSC Norfolk Southern
$256.04 /

-0.51 (-0.20%)

UNP Union Pacific
$208.02 /

-1.15 (-0.55%)

GWR Genesee & Wyoming
$111.91 /

+ (+0.00%)

CNI Canadian National
$111.53 /

-0.41 (-0.37%)

02/25/21 Evercore ISI
Canadian National upgraded to Outperform at Evercore in rail ratings shake-up
02/25/21 Evercore ISI
Canadian National upgraded to Outperform from In Line at Evercore ISI
01/28/21 Desjardins
Canadian National price target lowered to C$146 from C$150 at Desjardins
01/27/21 CIBC
Canadian National price target lowered to C$142 from C$153 at CIBC
CP Canadian Pacific
$362.88 /

-4.155 (-1.13%)

02/25/21 Evercore ISI
Canadian Pacific downgraded to In Line at Evercore in rail ratings shake-up
02/25/21 Evercore ISI
Canadian Pacific downgraded to In Line from Outperform at Evercore ISI
02/04/21 Argus
Canadian Pacific price target raised to $390 from $350 at Argus
01/28/21 CIBC
Canadian Pacific price target lowered to C$490 from C$500 at CIBC
CSX CSX
$91.87 /

-0.26 (-0.28%)

01/25/21 Argus
CSX price target raised to $98 from $90 at Argus
01/22/21
Fly Intel: Top five analyst downgrades
01/22/21 Cowen
CSX price target raised to $91 from $84 at Cowen
01/22/21 Stifel
CSX downgraded to Hold on valuation at Stifel
KSU Kansas City Southern
$207.00 /

-3.04 (-1.45%)

01/28/21 Deutsche Bank
Kansas City Southern price target raised to $212 from $197 at Deutsche Bank
01/25/21 BMO Capital
Kansas City Southern price target raised to $240 from $215 at BMO Capital
01/25/21 Wells Fargo
Kansas City Southern price target raised to $257 from $236 at Wells Fargo
01/25/21 Cowen
Kansas City Southern price target raised to $246 from $203 at Cowen
NSC Norfolk Southern
$256.04 /

-0.51 (-0.20%)

02/25/21 Evercore ISI
Norfolk Southern downgraded to In Line at Evercore in rail ratings shake-up
02/25/21 Evercore ISI
Norfolk Southern downgraded to In Line from Outperform at Evercore ISI
02/01/21 Argus
Norfolk Southern price target raised to $275 from $225 at Argus
01/28/21 Credit Suisse
Norfolk Southern price target lowered to $271 from $283 at Credit Suisse
UNP Union Pacific
$208.02 /

-1.15 (-0.55%)

01/22/21 Baird
Union Pacific positions should be increased on pullbacks, says Baird
01/20/21 Susquehanna
Railroad recovery expected to continue in 2021, says Susquehanna
01/15/21 Raymond James
Union Pacific price target raised to $250 from $220 at Raymond James
01/12/21 JPMorgan
Union Pacific price target raised to $216 from $212 at JPMorgan
GWR Genesee & Wyoming
$111.91 /

+ (+0.00%)

CNI Canadian National
$111.53 /

-0.41 (-0.37%)

CP Canadian Pacific
$362.88 /

-4.155 (-1.13%)

CSX CSX
$91.87 /

-0.26 (-0.28%)

KSU Kansas City Southern
$207.00 /

-3.04 (-1.45%)

NSC Norfolk Southern
$256.04 /

-0.51 (-0.20%)

UNP Union Pacific
$208.02 /

-1.15 (-0.55%)

KSU Kansas City Southern
$207.00 /

-3.04 (-1.45%)

NSC Norfolk Southern
$256.04 /

-0.51 (-0.20%)

UNP Union Pacific
$208.02 /

-1.15 (-0.55%)

CSX CSX
$91.87 /

-0.26 (-0.28%)

KSU Kansas City Southern
$207.00 /

-3.04 (-1.45%)

UNP Union Pacific
$208.02 /

-1.15 (-0.55%)

CSX CSX
$91.87 /

-0.26 (-0.28%)

UNP Union Pacific
$208.02 /

-1.15 (-0.55%)

Recommendations
Weir Group price target raised to 2,470 GBp from 2,190 GBp at RBC Capital » 13:30
03/03/21
03/03
13:30
03/03/21
13:30
WEGRY

Weir Group

$0.00 /

+ (+0.00%)

RBC Capital analyst Mark…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
WEGRY Weir Group
$0.00 /

+ (+0.00%)

02/11/21 Goldman Sachs
Weir Group reinstated with a Neutral at Goldman Sachs
02/08/21 Morgan Stanley
Weir Group upgraded to Overweight from Equal Weight at Morgan Stanley
01/13/21 Barclays
Weir Group price target raised to 2,350 GBp from 2,000 GBp at Barclays
01/12/21 Deutsche Bank
Weir Group price target raised to 2100 GBp from 1960 GBp at Deutsche Bank

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.